Table 2.
Reported adherence by patients to their new medicine (measured using the NMS question and Morisky Eight-Item Medication Adherence Scale (MMAS-8) and intention-to-treat analysis of the intervention as a predictor of adherence at weeks 10 and 26—frequency counts, unadjusted, adjusted and imputed ORs
| Intention-to-treat analysis at week 10 or 26 follow-up | Adherent patients/total responses, n (%), P value | Model 1* (naïve) OR (95% CI, P value) |
Model 2 (main/adjusted) OR (95% CI, P value) |
Model 3 (imputation) OR (95% CI, P value) |
| 10-week follow-up: adherence as assessed by NMS question (n=378) | ||||
| Normal practice | 115/190 (60.5) | 1.00 | 1.00 | 1.00 |
| NMS intervention | 133/188 (70.7), 0.037 | 1.58 (1.03 to 2.42, 0.037) | 1.67 (1.06 to 2.62, 0.027) | 1.62 (1.04 to 2.53, 0.032) |
| 26-week follow-up: adherence as assessed by NMS question (n=327) | ||||
| Normal practice | 97/170 (57.1) | 1.00 | 1.00 | 1.00 |
| NMS intervention | 103/157 (65.6), 0.113 | 1.44 (0.92 to 2.25, 0.114) | 1.50 (0.93 to 2.44, 0.095) | 1.50 (0.89 to 2.51, 0.127) |
| Secondary outcomes (adherence as assessed by MMAS-8) | ||||
| 10-week follow-up adherence MMAS-8 (n=267) | ||||
| Normal practice | 85/143 (59.4) | 1.00 | 1.00 | 1.00 |
| NMS intervention | 89/124 (71.8), 0.035 | 1.74 (1.04 to 2.90, 0.036) | 1.88 (1.06 to 3.34, 0.030) | 1.77 (0.96 to 3.28, 0.068) |
| 26-week follow-up adherence MMAS-8 (n=223) | ||||
| Normal practice | 70/124 (56.5) | 1.00 | 1.00 | 1.00 |
| NMS intervention | 63/99 (63.6), 0.277 | 1.35 (0.79 to 2.32, 0.278) | 1.60 (0.84 to 3.06, 0.153) | 1.43 (0.70 to 2.91, 0.320) |
*Model 1 (naïve): simple logistic regression model. Model 2 (main/adjusted): logistic regression model adjusted for recruiting pharmacy, disease, age, sex and medication count. Model 3 (imputation): adjusted logistic regression model taking imputation of missing data into account.
NMS, New Medicine Service.